|
| 37016669 | Reduced effectiveness of repeat influenza vaccination: distinguishing among within-season waning, recent clinical infection, and subclinical infection. | medRxiv | 2024 |
| 37633258 | Clinical Epidemiology and Risk Factors for Critical Outcomes Among Vaccinated and Unvaccinated Adults Hospitalized With COVID-19-VISION Network, 10 States, June 2021-March 2023. | Clin Infect Dis | 2024 |
| 37972288 | Vaccine Effectiveness Against Pediatric Influenza-A-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2022-2023 Season: VISION Network. | Clin Infect Dis | 2024 |
| 36327388 | Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022. | Clin Infect Dis | 2023 |
| 37965644 | Effectiveness of the Original Monovalent Coronavirus Disease 2019 Vaccines in Preventing Emergency Department or Urgent Care Encounters and Hospitalizations Among Adults With Disabilities: VISION Network, June 2021-September 2022. | Open Forum Infect Dis | 2023 |
| 37917142 | Work Attendance with Acute Respiratory Illness Before and During COVID-19 Pandemic, United States, 2018-2022. | Emerg Infect Dis | 2023 |
| 37663086 | Humoral Immune Response to Messenger RNA Coronavirus Disease 2019 Vaccination Among Children Aged 5-11 Years in a Multisite Prospective Cohort Study, September 2021-September 2022. | Open Forum Infect Dis | 2023 |
| 38014151 | Antibody response to symptomatic infection with SARS-CoV-2 Omicron variant viruses, December 2021-June 2022. | medRxiv | 2023 |
| 37796753 | Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged â¿¥60 Years - IVY Network, 20 U.S. States, February 2022-May 2023. | MMWR Morb Mortal Wkly Rep | 2023 |
| 37590187 | Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months-5 Years - VISION Network, United States, July 2022-June 2023. | MMWR Morb Mortal Wkly Rep | 2023 |
| 38000964 | Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design. | Vaccine | 2023 |
| 37790578 | Anti-SARS-CoV-2 Antibody Levels Associated with COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu VE Network, October 2021-June 2022. | medRxiv | 2023 |
| 37745498 | Determinants of <i>de novo</i> B cell responses to drifted epitopes in post-vaccination SARS-CoV-2 infections. | medRxiv | 2023 |
| 37479609 | Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021. | Vaccine | 2023 |
| 38041853 | Influenza vaccine effectiveness against influenza-A-associated emergency department, urgent care, and hospitalization encounters among U.S. adults, 2022-2023. | J Infect Dis | 2023 |
| 37816422 | Serum per- and polyfluoroalkyl substance concentrations and longitudinal change in post-infection and post-vaccination SARS-CoV-2 antibodies. | Environ Res | 2023 |
| 35580849 | Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States. | Clin Infect Dis | 2023 |
| 37394267 | Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023. | Am J Transplant | 2023 |
| 37255285 | Changing Severity and Epidemiology of Adults Hospitalized With Coronavirus Disease 2019 (COVID-19) in the United States After Introduction of COVID-19 Vaccines, March 2021-August 2022. | Clin Infect Dis | 2023 |
| 37246146 | Prior SARS-CoV-2 infection and COVID-19 vaccine effectiveness against outpatient illness during widespread circulation of SARS-CoV-2 Omicron variant, US Flu VE network. | Influenza Other Respir Viruses | 2023 |
| 37104244 | Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period - IVY Network, 19 U.S. States, February 1, 2022-January 31, 2023. | MMWR Morb Mortal Wkly Rep | 2023 |
| 37305842 | Immunogenicity of High-Dose Egg-Based, Recombinant, and Cell Culture-Based Influenza Vaccines Compared With Standard-Dose Egg-Based Influenza Vaccine Among Health Care Personnel Aged 18-65 Years in 2019-2020. | Open Forum Infect Dis | 2023 |
| 37333688 | Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort study. | Lancet Reg Health Am | 2023 |
| 37301704 | Comparison of mRNA vaccine effectiveness against COVID-19-associated hospitalization by vaccination source: Immunization information systems, electronic medical records, and self-report-IVY Network, February 1-August 31, 2022. | Vaccine | 2023 |
| 37227984 | Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023. | MMWR Morb Mortal Wkly Rep | 2023 |
| 37026401 | Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents. | Pediatrics | 2023 |
| 36960655 | Influenza Vaccine Effectiveness Among Children: 2011-2020. | Pediatrics | 2023 |
| 36883903 | Total and Subgenomic RNA Viral Load in Patients Infected With SARS-CoV-2 Alpha, Delta, and Omicron Variants. | J Infect Dis | 2023 |
| 36921274 | Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. | MMWR Morb Mortal Wkly Rep | 2023 |
| 36694363 | Prevalence and Clinical Outcomes of Respiratory Syncytial Virus vs Influenza in Adults Hospitalized With Acute Respiratory Illness From a Prospective Multicenter Study. | Clin Infect Dis | 2023 |
| 36920396 | Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. | JAMA Netw Open | 2023 |
| 36611252 | Relationships Between Social Vulnerability and Coronavirus Disease 2019 Vaccination Coverage and Vaccine Effectiveness. | Clin Infect Dis | 2023 |
| 36578137 | Severe Acute Respiratory Syndrome Coronavirus 2 Infection History and Antibody Response to 3 Coronavirus Disease 2019 Messenger RNA Vaccine Doses. | Clin Infect Dis | 2023 |
| 36806690 | Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19-Associated Encounters in Adults During Delta and Omicron Predominance. | J Infect Dis | 2023 |
| 36683410 | Vaccine Effectiveness Against Influenza-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2021-2022 Season, VISION Network. | J Infect Dis | 2023 |
| 36504336 | Influenza Vaccine Effectiveness Against Influenza A(H3N2)-Related Illness in the United States During the 2021-2022 Influenza Season. | Clin Infect Dis | 2023 |
| 36703252 | Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline Workers. | Emerg Infect Dis | 2023 |
| 36599411 | Relationship between Telework Experience and Presenteeism during COVID-19 Pandemic, United States, March-November 2020. | Emerg Infect Dis | 2023 |
| 36415904 | Protection of Two and Three mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized With COVID-19-VISION Network, August 2021 to March 2022. | J Infect Dis | 2023 |
| 36031405 | Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial. | Clin Infect Dis | 2023 |
| 34320171 | Vaccine Effectiveness Against Acute Respiratory Illness Hospitalizations for Influenza-Associated Pneumonia During the 2015-2016 to 2017-2018 Seasons: US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). | Clin Infect Dis | 2022 |
| 35710506 | Vaccine-associated attenuation of subjective severity among outpatients with influenza. | Vaccine | 2022 |
| 35675695 | Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States. | Clin Infect Dis | 2022 |
| 35665629 | Detection and Stability of SARS-CoV-2 in Three Self-Collected Specimen Types: Flocked Midturbinate Swab (MTS) in Viral Transport Media, Foam MTS, and Saliva. | Microbiol Spectr | 2022 |
| 35635842 | Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT): Protocol for a Multisite Longitudinal Cohort Study. | JMIR Res Protoc | 2022 |
| 35852804 | COVID-19 Vaccination Perspectives and Illnesses Among Law Enforcement Officers, Firefighters, and Other First Responders in the US, January to September 2021. | JAMA Netw Open | 2022 |
| 35818721 | Ascertainment of vaccination status by self-report versus source documentation: Impact on measuring COVID-19 vaccine effectiveness. | Influenza Other Respir Viruses | 2022 |
| 35862287 | Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022. | MMWR Morb Mortal Wkly Rep | 2022 |
| 35358170 | Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. | MMWR Morb Mortal Wkly Rep | 2022 |
| 35684961 | Multiplex Detection of Antibody Landscapes to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/Influenza/Common Human Coronaviruses Following Vaccination or Infection With SARS-CoV-2 and Influenza. | Clin Infect Dis | 2022 |